We conducted an open-label , randomized noninferiority trial comparing 3 months of directly observed once-weekly therapy with rifapentine ( 900 mg ) plus isoniazid ( 900 mg ) ( combination-therapy group ) with 9 months of self-administered daily isoniazid ( 300 mg ) ( isoniazid-only group ) in subjects at high risk for tuberculosis .
